Evidence map›Paper›PMID 41419850›Full record

ArticleBMC cancer2025

Impact of bilateral surgery on time to treatment in patients with breast cancer undergoing mastectomy - a retrospective cohort study.

Martin Heidinger, Sarah Staehelin, Florian S Halbeisen, Nadia Maggi, Julie M Loesch, Rama Kiblawi, Marie Louise Frevert, Fabienne D Schwab, Christian Kurzeder, Giacomo Montagna and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martin Heidinger *Breast Clinic, University Hospital Basel, Basel, Switzerland.
Sarah Staehelin *Breast Clinic, University Hospital Basel, Basel, Switzerland.
Florian S HalbeisenSurgical Outcome Research Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Nadia MaggiBreast Clinic, University Hospital Basel, Basel, Switzerland.
Julie M LoeschBreast Clinic, University Hospital Basel, Basel, Switzerland.
Rama KiblawiBreast Clinic, University Hospital Basel, Basel, Switzerland.
Marie Louise FrevertBreast Clinic, University Hospital Basel, Basel, Switzerland.
Fabienne D SchwabBreast Clinic, University Hospital Basel, Basel, Switzerland.
Christian KurzederBreast Clinic, University Hospital Basel, Basel, Switzerland.
Giacomo Montagna *University of Basel, Spitalstrasse 21, Basel, 4051, Switzerland.
Walter P Weber *Breast Clinic, University Hospital Basel, Basel, Switzerland. walter.weber@usb.ch.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionIt is unclear whether patients with breast cancer (BC) who undergo mastectomy experience delays in adjuvant treatment when bilateral surgery is performed. This study was conducted with the objective of addressing this knowledge gap.

methodsStage 0-III BC patients who underwent mastectomy (including conventional mastectomy, nipple-sparing mastectomy [NSM], and skin-sparing mastectomy [SSM]) at a Swiss university hospital between 01/2013 and 12/2023 were identified from a prospectively maintained database. Multivariable Cox proportional hazards regression models were used to detect predictors of time to adjuvant treatment.

resultsA total of 394 patients were included, 308 (78.2%) of whom underwent unilateral mastectomy (UM) and 86 (21.8%) of whom underwent bilateral mastectomy (BM). Compared with patients who underwent UM, those who underwent BM were younger (median age [years] 49 vs. 60), more likely to carry a pathogenic germline BRCA variant (28.7% vs. 2.6%), presented with bilateral breast cancer (14.9% vs. 0%), and underwent neoadjuvant chemotherapy (34.5% vs. 12.4%). Patients who underwent BM were more likely to receive NSM or SSM (81.4% vs. 52.9%) and to develop wound healing disorders (20.7% vs. 11.4%). On univariable analysis, no differences in time to any adjuvant treatment were observed between BMs and UMs (median [days] 34 vs. 33; p = 0.444). Multivariable analysis suggested that bilateral mastectomy was associated with a shorter time to adjuvant chemotherapy (HR 2.54, 95% CI 1.15-5.58). Short-term postoperative complications were associated with prolonged time to any adjuvant treatment (HR 0.50, 95% CI 0.36-0.71) and time to adjuvant chemotherapy (HR 0.37, 95% CI 0.17-0.79).

conclusionUndergoing BM did not result in a delay in time to adjuvant treatment in comparison to UM.

Indexed as

Breast NeoplasmsMastectomyTime-to-TreatmentAdultAgedChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoadjuvant TherapyProportional Hazards ModelsRetrospective StudiesAdjuvant treatmentBilateral mastectomyBreast cancerRisk-reducing mastectomy

Identifiers

PMID41419850
PMCPMC12837041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.